Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT01372540 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Leukemia
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

DRUG: Carfilzomib
DRUG: Filanesib
OTHER: Laboratory Biomarker Analysis

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]